HJHyesu Jo

Hyesu Jo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hyesu Jo has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparative burden of HIV and non-HIV sexually transmitted infections in Asia, 1990 to 2023

    by Dain Y. Kim, Jeongseon Oh, Jaeyu Park, Jaehyeong Cho, Jiyeon Oh, Hyeon Jin Kim, Jiseung Kang, Hyesu Jo, Hyunjee Kim, Jee Myung Yang, et al.

    Sexually transmitted infections (STIs) remain an important public health challenge in Asia, yet comparative evidence assessing human immunodeficiency virus (HIV) and non-HIV STIs within a unified regional framework is limited. Using the Global Burden of Diseases, Injuries, and Risk Factors Study 2023 estimates, we assessed HIV and non-HIV STIs (including syphilis, chlamydia, gonorrhea, trichomoniasis, and genital herpes) across 5 Asian subregions (Central, East, South, and Southeast Asia, and high-income Asia Pacific) from 1990 to 2023. We quantified burden using age-standardized disability-adjusted life-year rates and prevalence rates, analyzed temporal trends using estimated annual percentage changes, and examined attributable risk factors including unsafe sex, childhood sexual abuse, drug use, and intimate partner violence. From 1990 to 2023, HIV burden increased across most Asian subregions, while non-HIV STIs generally declined. In 2023, Southeast Asia showed the highest HIV burden and the highest prevalence of non-HIV STIs. HIV exhibited regionally variable age peaks and a predominantly male burden, while non-HIV STIs were concentrated in earlier adulthood and showed discordant sex patterns, with higher prevalence in males but higher disability-adjusted life-year rates in females. Unsafe sex was the leading attributable risk factor across regions, except in Central Asia, where drug use predominated for HIV-attributable burden. These findings underscore the need for differentiated responses across Asia, including sustained HIV-case finding and treatment scale-up, targeted harm reduction, and strengthened STI surveillance and prevention in higher-burden settings.

  • Open Access

    National trends of unmet healthcare needs and risk factors by household income level, 2010 to 2022: A Nationwide cross-sectional study in South Korea

    by Hyunjee Kim, Jaeyu Park, Jinyoung Jeong, Saiah Kim, Hayeon Lee, Hyeon Jin Kim, Yejun Son, Soeun Kim, Sooji Lee, Kyeongmin Lee, et al.

    Socio-economic status plays a critical role in shaping unmet healthcare needs, and the COVID-19 pandemic has further intensified these disparities; however, research to date remains insufficient. Therefore, this study aims to analyze unmet healthcare needs by household income using large-scale longitudinal data (2010–2022) including pre- and post- pandemic differences. This large-scale study (n = 2,628,584) utilized nationwide data from the Korea Community Health Survey (KCHS) conducted between 2010 and 2022, administered by the Korea Disease Control and Prevention Agency. The analysis employed complex, weighted sampling to examine trends in unmet healthcare needs, with a specific focus on changes during the COVID-19 pandemic. Weighted logistic regression models were used to calculate odds ratios and β differences (β diff ) between the pre-pandemic (2010–2019) and pandemic (2020–2022) periods. In total, 2,628,584 individuals participated in the KCHS from 2010 to 2022, comprising 1,454,129 males (55.3%) and 1,174,455 females (44.7%). Before the pandemic, there was a consistent decline in the prevalence of unmet healthcare needs. However, following the onset of the pandemic, unmet healthcare needs increased (β diff, low-level of household income: 1.66 [95% CI, 1.41–1.92]; mid-level of household income: 0.88 [95% CI, 0.77–0.99]; high-level of household income: 0.71 [95% CI, 0.57–0.85]). Overall, households with lower incomes exhibited higher levels of unmet healthcare needs compared to those with higher incomes (low household income: 14.8 [95% CI, 13.91–14.24]; high household income: 8.45 [95% CI, 8.34–8.55]). Additionally, the disparity in healthcare access due to income differences was more pronounced among older individuals, those with lower educational attainment, and those with lower subjective health status. Our analysis found that older adults in low-income households consistently faced higher rates of unmet healthcare needs. The reversal of a pre-pandemic trend toward reducing healthcare gaps highlights the urgent need for targeted interventions to address socio-economic disparities.


  • Open Access

    Global epidemiology of vaccine-associated intussusception in children and adolescents, 1968 to 2024: An international pharmacovigilance study

    by Tae Hyeong Kim, Hyesu Jo, Damiano Pizzol, Lee Smith, Dong Keon Yon

    Rotavirus vaccine associated intussusception has been investigated to some extent, limited research exists on intussusception caused by all vaccines from a comprehensive, global perspective. Thus, this study aimed to investigate the global burden of vaccine-associated intussusception using a comprehensive pharmacovigilance database. This study was conducted using data from the global pharmacovigilance database from 1968 to 2024. Reports of intussusception were identified by MedDRA code and categorized by vaccine type, age, sex, and region. Statistical disproportionality analysis was performed using reporting odds ratios (ROR) with 95% confidence interval (CI) and information components (IC) with IC 025 to assess vaccine-specific signal detections. Among 35 million vaccine-associated total adverse events, 12,055 reports of vaccine-associated intussusception were identified. Rotavirus vaccines exhibited the strongest signal detections with intussusception (ROR, 70.16 [95% CI, 67.56–72.86]; IC, 5.27 [IC 025 , 5.22]), followed by diphtheria, tetanus, acellular pertussis, polio, and Haemophilus influenzae type b (ROR, 3.82 [95% CI, 3.67–3.97]; IC, 1.55 [IC 025 , 1.49]) and pneumococcal vaccines (ROR, 8.54 [95% CI, 8.13–8.96]; IC, 2.84 [IC 025 , 2.77]). The mean time to onset was 2.77 days, with a low fatality rate (0.07%). While our findings do not allow for causal conclusions, the results of this study suggest that rotavirus vaccines may be associated with a slight increase in the risk of intussusception. However, it is important to note that their benefits in preventing severe diarrheal disease far outweigh the risks.

  • Open Access

    National trends in the prevalence of hypertension and diabetes stratified by sleep duration in South Korea, 2009–2022: A nationwide cross-sectional study: Trends and association of sleep duration in hypertension and diabetes

    by Jinyoung Jeong, Hyunjee Kim, Jaeyu Park, Hyeon Jin Kim, Hyesu Jo, Sooji Lee, Kyeongmin Lee, Seoyoung Park, Yesol Yim, Ho Geol Woo, et al.

    The increase in sleep-related issues is associated with various health problems, particularly hypertension and diabetes. Therefore, this study aims to address these gaps in the literature by analyzing the relationship between sleep duration and the prevalence of hypertension and diabetes. This study analyzed the association between hypertension, diabetes, and sleep duration using the Korea Community Health Survey database from 2009 to 2022. The study used weighted linear regression models to identify trends in diseases and sleep duration. Additionally, this analysis employed weighted logistic regression to examine associations between diseases and covariates, presented as weighted odds ratio (wOR) and 95% confidence intervals (CIs). Our analysis included 2,903,887 individuals aged ≥19 years. The prevalence of individuals with both hypertension and diabetes increased before (β, 0.87 [95% CI, 0.83–0.90]) and during the COVID-19 pandemic (β, 0.64 [0.58–0.70]). This trend was particularly notable among individuals who sleep less than 6 hours, with an increase identified both before (β, 1.28 [1.16–1.40]) and during the pandemic (β, 1.21 [1.03–1.39]). The higher risk of having both conditions was found in individuals who slept 8 hours (wOR, 1.19 [1.17–1.22]) compared to those who slept 7 to 8 hours. Our study is the first to analyze the association between sleep duration and hypertension and diabetes by utilizing a large-scale dataset and conducting a comparative analysis between the pre-COVID-19 and COVID-19 periods. This study shows that inadequate sleep is associated with an increased risk of hypertension and diabetes.


  • Open Access

    Global burden of TNF-α inhibitors associated demyelinating diseases: A global disproportionality analysis

    by Tae Hyeon Kim, Jaeyu Park, Hyesu Jo, Jeongseon Oh, Ho Geol Woo, Dong Keon Yon

    Despite case reports linking tumor necrosis factor-alpha (TNF-α) inhibitors to demyelinating diseases, large-scale epidemiological evidence is limited. We aimed to investigate this signal detection using a global pharmacovigilance database. This study identified reports of TNF-α inhibitor-associated demyelinating disease utilizing a global pharmacovigilance database spanning from 1968 to 2024. Five TNF-α inhibitors (infliximab, adalimumab, etanercept, certolizumab pegol, and golimumab) were included in this study. The signal detection between TNF-α inhibitors and demyelinating disease was evaluated using disproportionality analysis with 2 metrics: the information component (IC) with a threshold of IC 025 , and the reporting odds ratio (ROR) with a 95% confidence interval (CI). Statistical significance was defined as an IC 025 > 0.00 and the lower bound of the CI > 1.00. A total of 4124 reports of demyelinating diseases associated with TNF-α inhibitor use were identified. Multiple sclerosis was the most frequently reported condition (n = 2079, 50.41%). Overall, TNF-α inhibitors indicated a significant association with demyelinating diseases (ROR, 1.81 [95% CI: 1.75–1.87]; IC, 0.84 [IC 025 , 0.78]). Significant signal detections were observed for all 5 individual TNF-α inhibitors. Both multiple sclerosis (ROR, 1.52 [95% CI: 1.46–1.59]; IC, 0.60 [IC 025 , 0.43]) and Guillain–Barré syndrome (ROR, 1.53 [95% CI: 1.40–1.68]; IC, 0.60 [IC 025 , 0.45]) showed significant signal detection with TNF-α inhibitors. This large-scale pharmacovigilance study confirmed significant signal detection between TNF-α inhibitors and several demyelinating diseases, particularly multiple sclerosis and Guillain–Barré syndrome, with signals observed across most agents. Clinicians should remain vigilant for neurological symptoms in patients receiving these therapies. Although this disproportionality analysis did not permit causal interpretation, it is important to recognize that the therapeutic benefits of TNF-α inhibitors in managing inflammatory and autoimmune diseases may still outweigh these potential risks.


  • Open Access

    Global estimates of vaccine-associated narcolepsy from 1967 to 2023

    by Yi Deun Jeong, Hyesu Jo, Yesol Yim, Sooji Lee, Jaeyu Park, Jinseok Lee, Jiseung Kang, Louis Jacob, Lee Smith, Masoud Rahmati, et al.

    Regional evidence on the signal detection between narcolepsy and vaccines is scarcely available and insufficiently understood, thus impeding a comprehensive understanding of this relationship on a global scale. Therefore, this study aimed to evaluate the global estimates of vaccine-associated narcolepsy, discern its association with specific vaccines, and thereby contribute to the advancement of more efficient vaccination protocols. This study utilized data from the international pharmacovigilance database concerning vaccine-associated narcolepsy from 1967 to 2023. Global reporting counts, reported odds ratios (ROR), and information components (IC) were analyzed to identify the signal detection between the 16 vaccines and the occurrence of vaccine-associated narcolepsy across 140 countries. We identified 2,183 reports (male, n = 870 [39.85%]) of vaccine-associated narcolepsy from 5,291 reports of narcolepsy. Vaccine-associated narcolepsy has been reported since 2009. The highest disproportionality signals for narcolepsy were observed with influenza vaccines (ROR, 156.53 [95% CI, 147.62-165.97]; IC, 6.72 [IC0.25, 6.63]), followed by papillomavirus and encephalitis vaccines. Concerning age and sex-specific signals, reports of vaccine-associated narcolepsy were associated with age groups between 12 and 17 years and males. Most of these adverse events had a long time to onset (mean: 115 days). Although our findings do not permit any inference of causality, influenza vaccines showed highest signal detection between vaccines and narcolepsy followed by papillomavirus and encephalitis vaccines. COVID-19 mRNA vaccines, despite large number of reports, showed no evidence of signal detection with narcolepsy.